Skip to main content
. 2020 Apr 14;15(4):e0231573. doi: 10.1371/journal.pone.0231573

Table 2. Individual response data of mucosal thickness during treatment and follow-up period in the dose finding study.

Subject number Received dose P60.4Ac (mg/ml) Mucosal thickness score during treatment and follow-up period (week)a 0 1 2 4 8 12
01 0.25 2 1 1 0 0 1 b
02 0.25 2 0 1 b 0 0 0
03 0.25 3 1 1 1 0 0
04 0.25 3 2 1 1 2 2
05 0.5 3 1 1 2 2 2
06 0.5 1 1 0 0 0 0
07 0.5 2 2 1 0 0 0
08 0.5 1 1 2 1 0 1
09 1.0 3 1 0 0 0 0
10 1.0 3 2 2 1 0 0
11 1.0 3 2 2 3 2 2
12 1.0 3 2 2 2 3 2
13 2.0 2 1 2 2 2 2
14 2.0 2 2 2 2 1 3
15 2.0 3 3 2 1 2 0c
16 2.0 2 1 1 3 2 2

a Scores: 0: flat, dry mucosa; 1: flat, discharging mucosa; 2: thickened, polypoid, dry or discharging mucosa; 3: thickened polypoid tissue with viscous mucous discharge.

b Subject had a cold at that time.

c Subject had used an antibiotic treatment for frontal sinusitis.